Anti-Ipilimumab (Yervoy®) (Human) ELISA Kit

Product Overview

A Sandwich ELISA kit for the qualitative determination of antibody against Ipilimumab (Yervoy) in human serum or plasma.

Ipilimumab (Yervoy®) is a fully human IgG1κ antibody that binds to CTLA-4 (cytotoxic T lymphocyteassociated antigen 4), a molecule on T-cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be through T-cell - mediated anti-tumor immune responses. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. 96Trace’s BioSimTM anti-Ipilimumab ELISA kit is designed to detect antibody against Ipilimumab with high specificity and sensitivity in biological matrices.

Assay Information

Applications

This ELISA kit is used for Qualitative determination of antibody against Ipilimumab (Yervoy) in serum and plasma

Features & Benefits

• Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Ipilimumab (Yervoy) in human serum and plasma.
• Cross Reactivity: Ipilimumab (Yervoy®) infusion camouflages/masks the presence of antibody to Ipilimumab (ATP) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATP. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Ipilimumab.

Storage & Shipping

Product Details